Cetuximab is a recombinant human/mouse chimeric monoclonal antibody against epidermal growth factor receptor (EGFR). It is composed of the antigen-binding regions of mouse anti EGFR monoclonal antibody specific for the N-terminal portion of human EGFR with human IgG1 heavy and kappa light chain constant regions. Cetuximab is marketed under the brand Erbitux by Eli Lilly Company. It was approved by the US Food and Drug Administration for the trea™ent of metastatic colorectal cancer and metastatic non-small cell lung cancer.
GenScript MonoRab™ Anti-Cetuximab Antibody (69H10), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Cetuximab.